TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private ...
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement ...
TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the closing of its previously announced registered direct ...
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 ...
Profound Medical (Nasdaq:PROF) announced today that it sold shares of common stock worth proceeds of up to $40 million. Toronto-based Profound sold more than 5.1 million shares of common stock at a ...
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- ProFound™ Therapeutics, a Flagship Pioneering company pioneering the expanded human proteome to develop first-in-class medicines for multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results